|EDHF, NO and a prostanoid: hyperpolarization-dependent and -independent relaxation in guinea-pig arteries.|
|PMID: 10821789 Owner: NLM Status: MEDLINE|
|The contribution of endothelium-derived hyperpolarizing factor (EDHF), nitric oxide (NO) and a prostanoid (PG) to endothelium-dependent hyperpolarization and relaxation were assessed in coronary and mammary arteries of guinea-pigs by integration of the responses evoked during discrete applications of acetylcholine (ACh). The results of this integration approach were compared with those using traditional peak analysis methods. N(omega)-nitro-L-arginine methyl ester (L-NAME, 100 microM) and indomethacin (1 microM), alone or in combination, were without effect on peak hyperpolarizations or relaxations while they markedly reduced the integrated responses in both arteries. Integrated responses attributed to NO and PG were larger than those attributed to EDHF in the coronary artery (at 2 microM ACh, hyperpolarization (mV s): NO, 4200+/-91; PG, 5046+/-157; EDHF, 1532+/-94; relaxation (mN s mm(-1)): NO, 2488+/-122; PG, 2234+/-96; EDHF, 802+/-54). Integrated responses attributed to NO, PG and EDHF were similar in the mammary artery (at 2 microM ACh, hyperpolarization: NO, 347+/-69; PG, 217+/-49; EDHF, 310+/-63; relaxation: NO, 462+/-94; PG, 456+/-144; EDHF, 458+/-40). Gilbenclamide (1 microM) all but abolished the hyperpolarization attributable to NO and PG but not EDHF in both arteries allowing assessment of the role of the hyperpolarization in relaxation. Gilbenclamide was without effect on the integrated relaxation due to NO but significantly reduced the relaxation associated with PG in the two arteries. In conclusion, integration of the responses enabled a more complete assessment of the contribution of EDHF, NO and PG to endothelium-dependent responses, which were strikingly different in the two arteries. There is commonality in the role of hyperpolarization in relaxation in both arteries: EDHF-dependent relaxation is strongly dependent on hyperpolarization; hyperpolarization plays an important role in PG relaxation, whereas it has a small facilitatory role in NO-dependent relaxation.|
|M Tare; H C Parkington; H A Coleman|
Related Documents :
|2447399 - Possible role of endothelial thromboxane a2 in the resting tone and contractile respons...
20434959 - Vegf receptor 2 endocytic trafficking regulates arterial morphogenesis.
1673099 - In vitro responses of equine digital vessels to dopamine and fenoldopam.
2783499 - Effect of subarachnoid hemorrhage on calcitonin gene-related peptide-induced relaxation...
11564649 - Distinction between relaxations induced via prostanoid ep(4) and ip(1) receptors in pig...
8809209 - Possible involvement of endothelial leukotrienes in acetylcholine-induced contraction i...
12373249 - Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in ...
10617889 - Rare variation of the axillary artery.
3183329 - Huge splenic artery aneurysm after portocaval shunt.
|Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't|
|Title: British journal of pharmacology Volume: 130 ISSN: 0007-1188 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2000 Jun|
|Created Date: 2000-08-01 Completed Date: 2000-08-01 Revised Date: 2013-06-11|
Medline Journal Info:
|Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: ENGLAND|
|Languages: eng Pagination: 605-18 Citation Subset: IM|
|Department of Physiology, Monash University, Clayton, Victoria 3800, Australia. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Arteries / drug effects
Biological Factors / pharmacology*
Cyclooxygenase Inhibitors / pharmacology
Endothelium, Vascular / physiology
Enzyme Inhibitors / pharmacology
Glyburide / pharmacology
Hypoglycemic Agents / pharmacology
Indomethacin / pharmacology
Muscle Relaxation / drug effects
Muscle, Smooth, Vascular / drug effects*
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / pharmacology*
Nitric Oxide Synthase / pharmacology
Nitric Oxide Synthase Type III
Prostaglandins / pharmacology*
Vasoconstriction / drug effects
Vasoconstrictor Agents / pharmacology
|0/Biological Factors; 0/Cyclooxygenase Inhibitors; 0/Enzyme Inhibitors; 0/Hypoglycemic Agents; 0/Prostaglandins; 0/Vasoconstrictor Agents; 0/endothelium-dependent hyperpolarization factor; 10102-43-9/Nitric Oxide; 10238-21-8/Glyburide; 50903-99-6/NG-Nitroarginine Methyl Ester; 53-86-1/Indomethacin; 76898-47-0/15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; EC 18.104.22.168/Nitric Oxide Synthase; EC 22.214.171.124/Nitric Oxide Synthase Type III|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thermodynamically distinct high and low affinity states of the A(1) adenosine receptor induced by G ...
Next Document: Effects of halothane on the membrane potential in skeletal muscle of the frog.